Register Login
Register to leave comments
  • News bot Oct. 30, 2025, 11:03 a.m.

    📋 PHATHOM PHARMACEUTICALS, INC. (PHAT) - Financial Results

    Filing Date: 2025-10-30

    Accepted: 2025-10-30 07:00:14

    Event Type: Financial Results

    Event Details:

    Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2025 Financial Results Phathom Pharmaceuticals Inc (PHAT) announced its financial results for the period ending Q4 2025. Key Financial Highlights:
    • Revenue: 0.12
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 135156
      • Over 790,000 filled prescriptions for VOQUEZNA tablets, VOQUEZNA TRIPLE PAK®, and VOQUEZNA DUAL PAK® as of October 17,
      • • In the third quarter 2025, approximately 221,000 VOQUEZNA prescriptions were filled, a 28% increase quarter over quarter. Covered prescriptions grew 23% during the third quarter and continue to be the primary driver of revenue.
      • In July, sales force retargeting efforts commenced, focusing on deepening sales call engagement with gastroenterologists (GIs). In October, Phathom completed a national sales territory realignment consistent with this GI targeting focus.
        • targeting efforts commenced, focusing on deepening sales call engagement with gastroenterologists (GIs). In October, Phathom completed a national sales territory realignment consistent with this GI targeting focus. • VOQUEZNA commercial coverage remains stable with greater than 80% of U.S. commercial lives covered. Recent Business and Regulatory Updates: • The Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in Eosinophilic Esophagitis (EoE) was initiated in October 2025
        • anticipated in 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Operating Expenses Selling General Administrative 76.10K 231.35K $-155.25K -67.11%
    Loss From Operations 70.80K 154.06K $-83.26K -54.05%
    Other Expense Income Interest Income 3.71K 5.84K $-2.13K -36.46%
    Other Expense Income Interest Expense 18.48K 51.70K $-33.21K -64.24%
    Net Loss Per Share 1.05 2.00 $-0.95 -47.50%
    Reconciliation Of Gaap Tonongaapadjusted Net Loss Per Share Basic And Diluted Net Loss Per Share 1.32 2.76 $-1.44 -52.17%
    Selling General Administrative 4.34K 18.07K $-13.73K -75.98%
    Revenue 16.35K 117.53K $-101.17K -86.09%
    Selling, General & Administrative 76.10K 231.35K $-155.25K -67.11%
    Loss from Operations 70.80K 154.06K $-83.26K -54.05%
    Interest Income 3.71K 5.84K $-2.13K -36.46%
    Interest Expense 18.48K 51.70K $-33.21K -64.24%
    Net Loss 85.58K 200.10K $-114.52K -57.23%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Phathom Pharmaceuticals Inc
    • CIK: 0001783183
    • Ticker Symbol: PHAT
    • Period End Date: 2025-10-30
    • Document Type: 8-K

Search

News categories